In a patient with early‑stage (Kellgren‑Lawrence grade 1‑2) knee osteoarthritis who has tried weight loss, exercise, education, and simple analgesics, what are the indications, benefits, and recommended protocols for intra‑articular corticosteroid (cortisone) injection versus platelet‑rich plasma (PRP) injection?

Intra-articular Corticosteroid vs PRP for Early Knee Osteoarthritis

For patients with early-stage (KL grade 1-2) knee osteoarthritis who have failed conservative measures, intra-articular corticosteroid injection is the preferred first-line injectable therapy, providing reliable short-term relief (up to 3 months) with strong evidence support, while PRP should be reserved as a second-line option when corticosteroids fail or for patients seeking longer-term benefit beyond 3-6 months.

Evidence-Based Treatment Algorithm

First-Line Injectable: Corticosteroid

The 2022 AAOS guideline provides the strongest recommendation for corticosteroid injections, supported by 19 high-quality and 6 moderate-quality studies 1. Corticosteroids deliver predictable pain relief and functional improvement, though benefits typically last only 3 months 1.

Recommended protocol:

• Single intra-articular injection
• Expect symptom relief within 1 week 2
• Duration of benefit: 3 months on average 1
• Can repeat if symptoms recur after initial response
• Use lowest effective dose 3

Second-Line Injectable: PRP

The 2019 ACR/Arthritis Foundation guideline strongly recommends against PRP due to lack of standardization and heterogeneity in preparations 4. However, this conflicts with the 2022 AAOS guideline, which conditionally supports PRP based on 2 high-quality and 1 moderate-quality study showing reduced pain and improved function 1.

Critical caveat: PRP performs worse in severe osteoarthritis 1. Your KL grade 1-2 patient falls within the optimal treatment window where PRP demonstrates superior outcomes 5, 6.

Comparative Efficacy Timeline

Short-term (≤6 weeks):

• Corticosteroids superior 7
• CS achieves clinically meaningful pain reduction (MCID met for VAS and NPRS) 7
• PRP shows slower onset, with 75% experiencing mild self-limited synovitis in first week 2

Mid-term (3-6 months):

• PRP begins outperforming corticosteroids 2, 8
• At 15 weeks, PRP shows statistically significant improvements in VAS, IKDC, and KSS scores compared to CS 2

Long-term (≥1 year):

• PRP demonstrates sustained superiority 2, 8, 9
• PRP maintains pain relief and functional improvement at 1-year follow-up 2
• CS benefits diminish after 3 months 1

PRP Protocol When Indicated

Optimal parameters based on 2025 meta-analysis 5:

• Concentration: 600-900 × 10⁹/L platelets
• Injection series: 3-5 injections
• Interval: 7-14 days between injections
• Formulation: Leukocyte-rich PRP more effective than leukocyte-poor 8

Best candidates for PRP:

• KL grade I-II (your patient qualifies) 5
• Failed corticosteroid injection
• Seeking longer-term relief (>6 months)
• Willing to tolerate initial synovitis and delayed onset of benefit

Critical Pitfalls to Avoid

1. Don't use PRP as first-line therapy: Despite recent favorable research 5, 6, 8, 9, the ACR strongly recommends against it 4, and AAOS notes concerns about cost and safety profile 1. Start with proven, guideline-supported corticosteroids.

2. Don't expect immediate PRP results: Patients need counseling that PRP takes weeks to months for benefit, unlike CS which works within days 2, 7.

3. Don't use PRP in advanced OA: Evidence shows worse outcomes in severe disease (KL grade III-IV) 1.

4. Don't assume PRP standardization: Preparation methods vary wildly between providers, affecting outcomes 4, 10. If using PRP, ensure your facility follows evidence-based protocols 5.

5. Monitor for corticosteroid-related complications: Long-term or repeated CS injections risk cartilage damage, bone loss, and HPA axis suppression 3. Limit frequency and consider PRP if multiple injections needed.

Divergent Guideline Recommendations

The 2019 ACR strongly recommends against PRP 4, citing heterogeneity and lack of standardization. The 2022 AAOS conditionally supports PRP 1, acknowledging inconsistent evidence but recognizing benefit in selected patients. The 2026 AAPM&R guidance provides nuanced support for PRP with specific protocols 10.

Resolution of this conflict: Recent high-quality evidence (2025-2026) increasingly favors PRP for mid-to-long-term outcomes 5, 6, 8, 9, 11, but corticosteroids remain first-line due to established efficacy, lower cost, and guideline support. Use CS first; escalate to PRP if inadequate response or need for sustained benefit.

Practical Clinical Pathway

1. Confirm conservative measures exhausted: Weight loss, exercise, physical therapy, NSAIDs/acetaminophen 1

2. First injection: Corticosteroid

   • Expect 3 months of benefit
   • If inadequate relief or early recurrence → proceed to step 3

3. Second injection: Consider PRP series

   • 3-5 injections over 3-7 weeks
   • Counsel on delayed onset (weeks) and possible initial synovitis
   • Expect sustained benefit 6-12 months

4. If both fail: Reassess for surgical candidacy or alternative interventions